MCK
McKesson Corporation
NYSE · Healthcare · Medical - Distribution · US
$907.99
−1.45%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 411.0B | 403.4B | 359.1B | 309.0B | 276.7B |
| Cost of Revenue | 396.0B | 388.9B | 346.6B | 296.7B | 264.8B |
| Gross Profit | 15.0B | 14.6B | 12.5B | 12.2B | 11.9B |
| Operating Expenses | |||||
| R&D Expense | — | 103.0M | 91.0M | 77.0M | 89.0M |
| SG&A Expense | 4.1B | (8.1B) | 8.0B | 8.2B | 7.3B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | 44.0M | (8.1B) | — | — | — |
| Other Expenses | 4.2B | 16.1B | — | — | — |
| Total Operating Expenses | 8.3B | 8.1B | 8.1B | 8.3B | 7.4B |
| Cost and Expenses | 404.3B | 397.0B | 354.7B | 305.0B | 272.3B |
| Operating Income (EBIT) | 6.7B | 6.5B | 4.4B | 3.9B | 4.5B |
| Non-Operating | |||||
| Interest Income | — | 179.0M | 173.0M | 118.0M | 107.0M |
| Interest Expense | 153.0M | 247.0M | 256.0M | 243.0M | 248.0M |
| Net Interest Income | (153.0M) | (68.0M) | (83.0M) | (125.0M) | (141.0M) |
| Other Non-Op Income/Expense | (196.0M) | (253.0M) | (13.0M) | (138.0M) | 177.0M |
| Non-Operating Income (excl Interest) | 81.0M | 6.0M | (243.0M) | (105.0M) | (425.0M) |
| EBT (Pre-Tax Income) | 6.5B | 6.2B | 4.4B | 3.8B | 4.6B |
| Income Tax Expense | 1.2B | 1.1B | 878.0M | 629.0M | 905.0M |
| Bottom Line | |||||
| Net Income | 4.6B | 4.8B | 3.3B | 3.0B | 3.6B |
| Earnings from Cont. Ops | 5.3B | 5.1B | 3.5B | 3.2B | 3.7B |
| Earnings from Discont. Ops | — | — | — | — | (3.0M) |
| Bottom Line Net Income | 4.6B | 4.8B | 3.3B | 3.0B | 3.6B |
| Per Share | |||||
| Basic EPS | $37.53 | $38.55 | $25.86 | $22.54 | $25.23 |
| Diluted EPS | $37.37 | $38.38 | $25.72 | $22.39 | $25.04 |
| Revenue Per Share | $3,462.37 | $3,264.00 | $2,818.30 | $2,319.45 | $1,961.10 |
| Shares | |||||
| Basic Shares Outstanding | 118.7M | 123.6M | 127.4M | 133.2M | 141.1M |
| Diluted Shares Outstanding | 119.2M | 124.1M | 128.1M | 134.1M | 142.2M |
| Profitability Metrics | |||||
| EBITDA | 7.1B | 7.2B | 5.3B | 4.7B | 5.7B |
| D&A | 572.0M | 729.0M | 636.0M | 635.0M | 857.0M |
| EBIT | 6.6B | 6.4B | 4.6B | 4.0B | 4.9B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026